BAYLX,INC. Announces US FDA Clearance of IND Application for Its Umbilical Cord Tissue Mesenchymal Stem Cells Product to Initiate Clinical Trial in Rheumatoid Arthritis

IRVINE, Calif.–(BUSINESS WIRE)–Baylx, Inc. (Baylx), a clinical-stage biopharmaceutical company dedicated to developing novel stem cell therapeutics and products to address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared Baylx’s Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) product in patients with Rheumatoid Arthritis (RA). "We are pleased to have receiv